Monoclonal antibody therapy in lymphoid malignancies

Oncologist

Volumn 5, Issue 5, 2000, Pages 376-384

  Hainsworth, J D ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Indolent lymphoma; Large cell lymphoma; Monoclonal antibodies; Radioimmunoconjugates; Rituximab

Indexed keywords

ALEMTUZUMAB; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; LUGOL; LYMPHOCYTE ANTIGEN; MONOCLONAL ANTIBODY; OXYGEN; PETHIDINE; POTASSIUM IODIDE; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; TOSITUMOMAB; UNCLASSIFIED DRUG; VINCRISTINE; YTTRIUM IBRITUMOMAB TIUXETAN Y 90;

ADVANCED CANCER; CANCER CLASSIFICATION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; OXYGEN THERAPY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0033775935     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-5-376     Document Type: Review

References (42)

1. Monoclonal antibody-based therapies for hematologic malignancies
2. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody
3. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
4. IDEC-C2B8 Rituximab anti-CD-20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
5. IDEC-C2B8 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
6. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance
7. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
8. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression
9. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
10. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
11. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
12. Rituximab as first-line treatment of follicular lymphoma patients with low tumor burden. Preliminary results of a phase II trial
13. Early molecular responses in newly diagnosed follicular lymphoma patients with Rituximab as first-line treatment
14. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia
15. Rituxan has significant activity in patients with CLL
16. Infusion-related events following rituximab therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Association with inflammatory cytokines
17. Rituximab as initial therapy for patients with low-grade non-Hodgkin's lymphoma
18. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
19. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
20. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate or high-grade non-Hodgkin's lymphoma
21. Pilot study of Rituxan in combination with fludarabine chemotherapy in patients with low-grade or follicular non-Hodgkin's lymphoma
22. Rituximab (IDEC-C2B8) and CVP chemotherapy in follicular or low-grade B-cell lymphoma after relapse: Results after 6 months of follow-up
23. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
24. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project
25. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project
26. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
27. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)
28. Rituximab/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma
29. Phenotype and clinical evidence supports rituximab for Waldenstrom's macroglobulinemia
30. Rituximab is an active agent in Waldenstrom's macroglobulinemia
31. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
32. 131I] anti-B1 (anti-CD20) antibody
33. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
34. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphoma
35. Iodine I-131 tositumomab therapy for previously untreated follicular lymphoma
36. + B-cell non-Hodgkin's lymphoma
37. Interim results from a prospective randomized controlled trial comparing Zevalin radioimmunotherapy to rituximab immunotherapy for B-cell non-Hodgkin's lymphoma: Resistance to prior chemotherapy vs response rate
38. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas
39. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia
40. Campath-1H therapy in 29 patients with refractory CLL: 'True' complete remission is an attainable goal
41. Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia refractory to fludarabine
42. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma